



## PRESS RELEASE

---

### ASLAN PHARMACEUTICALS' ABSTRACT ON VARLITINIB WINS BEST POSTER AT ESMO ASIA 2017

**SINGAPORE, January 2, 2018** – ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that an abstract presented at ESMO Asia 2017 on data from its Phase 2 clinical trial of *varlitinib* in metastatic HER2-positive breast cancer (HER2+ MBC) patients won the Best Poster Award in the breast cancer, metastatic category.

*Varlitinib* is a reversible potent small molecule inhibitor of the HER-family of receptor tyrosine kinases (RTKs). The Phase 2 clinical trial compared the efficacy and safety of *varlitinib* plus *capecitabine* (VC) versus *lapatinib* plus *capecitabine* (LC) in HER2+ MBC patients who failed prior *trastuzumab* therapy.

Details of the abstract are as follows:

**Title:** Multicenter phase 2 trial of *varlitinib* versus *lapatinib* in combination with *capecitabine* in patients with HER2+ metastatic breast cancer (MBC) who failed prior *trastuzumab* therapy.

**Abstract Number:** 987

A full-text version of the abstract is available online at

<https://cslide.ctimeetingtech.com/asia2017/attendee/confcal/presentation/list?r=pt~23>

#### Media and IR contacts

**Chris Fang**

ASLAN Pharmaceuticals

Tel: +886 2 2758 3333

E-mail: [media@aslanpharma.com](mailto:media@aslanpharma.com)

**Emma Thompson / Stephanie Tan**

Spurwing Communications

Tel: +65 6340 7287

Email: [ASLAN@spurwingcomms.com](mailto:ASLAN@spurwingcomms.com)

**Robert H. Uhl**

Westwicke Partners

Tel: +1 858 356 5932

Email: [robert.uhl@westwicke.com](mailto:robert.uhl@westwicke.com)

#### About *varlitinib* (ASLAN001)

*Varlitinib* (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2, HER3 and HER4. These receptors can be mutated or overexpressed in many tumors, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, *varlitinib* could inhibit proliferation and control tumor growth. *Varlitinib* is currently being studied in biliary tract, gastric, breast and colorectal cancers. *Varlitinib* has been granted orphan drug designation in the United States for gastric cancer and cholangiocarcinoma, a sub-type of biliary tract cancer, and was awarded orphan drug designation for the treatment of biliary tract cancer by the Ministry of Food and Drug Safety in South Korea.



**About ASLAN Pharmaceuticals**

ASLAN Pharmaceuticals (ASLAN, 6497.TT) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN's portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN's partners include Array BioPharma, Bristol-Myers Squibb, Ammirall and CSL. For additional information please visit [www.aslanpharma.com](http://www.aslanpharma.com).